4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS

Compounds of Formula I:and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such...

Full description

Saved in:
Bibliographic Details
Main Authors Burgess, Laurence E, Hicken, Erik James, Chicarelli, Mark J, Robinson, John E, Hinklin, Ronald Jay, Fischer, John P, Rieger, Robert Andrew, Tang, Tony P, Boys, Mark Laurence, Pheneger, Jed, Raheja, Raj K, Satoh, Yoshitaka, Leftheris, Katerina, Allen, Shelley, Kraser, Christopher F, Bennett, Brydon L, Laird, Ellen, Fell, Jay Bradford, Gaudino, John
Format Patent
LanguageCroatian
English
Published 14.05.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Compounds of Formula I:and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
Bibliography:Application Number: HR2021P000501T